Strategies for chronic coronary disease: A brief guide for clinicians

Chayakrit Krittanawong, Muzamil Khawaja, Hafeez Ul Hassan Virk, Johao Escobar, Umair Khalid, Yochai Birnbaum, Carl J. Lavie, Samin Sharma, Hani Jneid, Sunil Rao, Salim S. Virani
{"title":"Strategies for chronic coronary disease: A brief guide for clinicians","authors":"Chayakrit Krittanawong, Muzamil Khawaja, Hafeez Ul Hassan Virk, Johao Escobar, Umair Khalid, Yochai Birnbaum, Carl J. Lavie, Samin Sharma, Hani Jneid, Sunil Rao, Salim S. Virani","doi":"10.1038/s44325-024-00006-w","DOIUrl":null,"url":null,"abstract":"The 2023 Multisociety Guidelines for the Management of Patients with Chronic Coronary Disease (CCD) is a collaborative effort between the American Heart Association (AHA) and the American College of Cardiology (ACC) that provides recommendations on the management of this condition. Efficient management of CCD involves non-pharmaceutical interventions that promote healthier lifestyles, such as increasing physical activity, adopting a balanced diet, and addressing tobacco misuse. These changes are critical to improving cardiovascular outcomes for individuals with CCD. In addition to lifestyle modifications, pharmacological and revascularization treatments also play an essential role in managing CCD. These treatments target the complex mechanisms of the disease, optimize cardiac function, and decrease the risk of adverse events. The combination of lifestyle changes and medicine-based medications enhances the quality of life and lowers mortality rates among individuals with CCD. This article review emphasizes the importance of non-pharmacological and pharmacological strategies that align with the AHA/ACC guidelines. In addition, the primary objective of this study is to enhance comprehension of the approaches that have led to better cardiovascular results for patients diagnosed with CCD.","PeriodicalId":501706,"journal":{"name":"npj Cardiovascular Health","volume":" ","pages":"1-15"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44325-024-00006-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Cardiovascular Health","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44325-024-00006-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The 2023 Multisociety Guidelines for the Management of Patients with Chronic Coronary Disease (CCD) is a collaborative effort between the American Heart Association (AHA) and the American College of Cardiology (ACC) that provides recommendations on the management of this condition. Efficient management of CCD involves non-pharmaceutical interventions that promote healthier lifestyles, such as increasing physical activity, adopting a balanced diet, and addressing tobacco misuse. These changes are critical to improving cardiovascular outcomes for individuals with CCD. In addition to lifestyle modifications, pharmacological and revascularization treatments also play an essential role in managing CCD. These treatments target the complex mechanisms of the disease, optimize cardiac function, and decrease the risk of adverse events. The combination of lifestyle changes and medicine-based medications enhances the quality of life and lowers mortality rates among individuals with CCD. This article review emphasizes the importance of non-pharmacological and pharmacological strategies that align with the AHA/ACC guidelines. In addition, the primary objective of this study is to enhance comprehension of the approaches that have led to better cardiovascular results for patients diagnosed with CCD.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性冠心病策略:临床医生简明指南
2023 年慢性冠状动脉疾病 (CCD) 患者管理多协会指南》是美国心脏协会 (AHA) 和美国心脏病学会 (ACC) 的一项合作成果,为这一疾病的管理提供了建议。对 CCD 的有效管理包括非药物干预,以促进更健康的生活方式,如增加体育锻炼、采用均衡饮食和解决烟草滥用问题。这些改变对于改善 CCD 患者的心血管预后至关重要。除改变生活方式外,药物治疗和血管重建治疗也在控制 CCD 方面发挥着重要作用。这些治疗针对疾病的复杂机制,优化心脏功能并降低不良事件的风险。改变生活方式与药物治疗相结合,可提高 CCD 患者的生活质量并降低死亡率。本文综述强调了与 AHA/ACC 指南一致的非药物和药物治疗策略的重要性。此外,本研究的主要目的是加深对已确诊为 CCD 患者的心血管治疗效果更好的方法的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A systematic review to identify assessment instruments for social isolation or loneliness in adults with heart failure. The association between proton pump inhibitors and the risk of gastrointestinal bleeding in oral anticoagulants users. Mechanisms and implications of vascular-homing CD8 T cells in atherosclerosis. Leveraging AI-enhanced digital health with consumer devices for scalable cardiovascular screening, prediction, and monitoring. Machine learning based, subject-specific, gender and race independent, non-invasive estimation of the arterial blood pressure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1